<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Open Science Publishers LLP</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">181</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> http://dx.doi.org/10.31782/IJMPS.2022.12301</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Perspectives of Anti-Cancer Phytoconstituents in Pharmacotherapy&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Asati</surname><given-names>Vivek</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>20</day><month>03</month><year>2022</year></pub-date><volume>)</volume><issue/><fpage>1</fpage><lpage>6</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>With 8.8 million people dying each year, cancer is the world__ampersandsignrsquo;s second-largest cause of mortality. Kidney cancer, prostate cancer, colorectal cancer, stomach cancer, and liver cancer are more common in males, whereas breast cancer, colorectal cancer, lung cancer, cervical cancer, and stomach cancer are more common in women. Several medicines, such as taxanes like paclitaxel and vinca alkaloids like vincristine and vinblastine, are derived from plants and are approved by the US Food and Drug Administration (USFDA) for use in cancer therapy. Nonetheless, a range of bioactive sources must be identified as soon as possible in order to develop a novel anti-cancer therapy for this chronic illness. More than thirty plant-derived natural compounds have been identified and are now being tested in clinical studies. According to a literature study of numerous papers and texts, novel therapeutic compounds generated from bioactive sources have been proven to be therapeutically efficacious against various types of cancer cells. The present study focuses on new therapeutic compounds derived from plants that have been proven in clinical trials to cure a range of malignancies. This paper also provided and analyzed the most significant findings of these effective new therapeutic medicines.&#13;
</p></abstract><kwd-group><kwd> Natural</kwd><kwd> Phytoconstituents</kwd><kwd> Anti-cancer</kwd><kwd> Chemotherapeutics</kwd><kwd> Cancer</kwd><kwd> Therapy</kwd></kwd-group></article-meta></front></article>
